Latest News

Page 2 of 3012345...102030...Last »

March 3, 2018

Aging Can Cause Eye Problems Other Than Low Vision Disease

Posted in: Daily Living, Latest News

by Ellen Troyer, MT MA CEO & Chief Research Officer, Biosyntrx Just as hair turns gray with age, bladders weaken and memories lapse, our eyes, too, undergo a metamorphosis. Although these changes are all part of normal aging, some set the stage for more serious eye problems. As eyes age, eyelid muscles weaken, and skin becomes
read more »

February 14, 2018

New Anti-Ang2 Drug for Wet AMD Showing Promise

Posted in: Latest News

It was reported here in November 2017 that two “anti-Ang2” drugs are being studied as potential combination therapies with established anti-VEGF treatments. RG7716 is being tested in combination with Lucentis (Genentech), and nesvacumab (REGN910) is being tested in combination with Eylea (Regeneron). Genentech has now reported that its Phase 2 BOULEVARD trials with RG7716 have
read more »

February 8, 2018

A Sight-Saving Valentine for Your Loved Ones

Posted in: Latest News

February is Age-Related Macular Degeneration Awareness Month, and Valentine’s Day is right in the middle. If you would like to send a unique valentine that expresses your love while serving a valuable purpose, read on. Please take this opportunity to teach others about macular degeneration and the need for early diagnosis. This is especially important information for
read more »

February 3, 2018

Low Vision Lighting Technology is Improving

Posted in: Daily Living, Latest News

by Dan Roberts Advancements in lighting technology for the visually impaired have made big strides during the past 12 years. Before 2005, companies were touting their new full spectrum (“daylight”) lamps as “healthy for aging eyes”. Patients, and even their doctors, were led to believe that the sun at high noon is the best and
read more »

January 26, 2018

First AMD Patient Receives Sub-Retinal Implant

Posted in: Latest News, Research and Developments

(Updated 4/17/18) Pixium Vision has announced its first successful human implantation of a wireless sub-retinal implant in a patient with atrophic dry age-related macular degeneration (AMD). So far, three patients have been implanted with the device, and results are promising. As reported here in October 2017, the implant, called PRIMA, acts like a tiny solar
read more »

January 11, 2018

Free Information Available to the Public for Glaucoma Awareness Month

Posted in: Latest News

Cases of Glaucoma, the “Sneak Thief of Sight,” Projected to Increase Significantly in Near Future As the population of the United States ages, the number of age-related eye disease cases is projected to grow.  Glaucoma, one of the most common eye diseases, currently affects nearly 3 million people ages 40 and older, according to the
read more »

January 8, 2018

New Educational Toolkit Launched to Improve Understanding of Age-related Macular Degeneration

Posted in: Latest News

A global coalition of patients and representative groups concerned with vision health, aging, and avoidable blindness has launched a central hub designed to bring the most up-to-date information on the various forms of Age-related Macular Degeneration (AMD) to patients, their representatives, health care providers, and policy makers. . The Toolkit, available at www.RETINA-AMD.org, was developed
read more »

December 21, 2017

Apellis Entering Phase 3 Trials for Dry Macular Degeneration

Posted in: Latest News, Research and Developments

Apellis Pharmaceuticals has announced that it has finalized the trial design for its planned Phase 3 program evaluating APL-2 for the treatment of patients with geographic atrophy (GA), aka dry macular degeneration. The Phase 3 program, planned to begin in the second half of 2018, will consist of two identical studies to assess the efficacy
read more »

December 20, 2017

FDA Approves First Gene Therapy for Inherited Retinal Dystrophy

Posted in: Latest News, Research and Developments, Therapies, Treatments, and Procedures

The U.S. Food and Drug Administration (FDA) has approved Luxturna (voretigene neparvovec-rzyl), a new gene therapy developed by Spark Therapeutics, to treat an inherited form of vision loss that can result in blindness.  The most prevalent inherited retinal dystrophies are retinitis pigmentosa (RP), Leber congenital amaurosis (LCA) and Stargardt disease (SD), all of which have
read more »

December 14, 2017

Help Your Ophthalmologist Help You

Posted in: Latest News, Low Vision Rehabilitation

Please share this article with your ophthalmologist Vision rehabilitation is the standard of care for patients who are losing their vision, and ophthalmologists are key to improving access to care for these patients. Recognizing this, Lighthouse Guild is offering ophthalmologists free access to an eLearning program titled, “Introduction to Vision Rehabilitation.” Dr. Alan R. Morse,
read more »

Page 2 of 3012345...102030...Last »

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann